Drugs / MVA PvDBP
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01816113 | Apr 2013 → Jul 2014 | Plasmodium vivax malaria | University of Oxford | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT04009096 | Jul 2019 → Jul 2022 | Plasmodium vivax malaria | University of Oxford | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MVA PvDBP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04009096 ↗ |
| Modality | Vaccine | “replication-deficient chimpanzee adenovirus serotype 63 (ChAd63) and modified vaccinia virus Ankara (MVA) viral vectored vaccines targeting PvDBP_RII” PMID 28614791 ↗ Jun 2017 |
| Route | Intramuscular | “Vaccines were delivered by the intramuscular route” PMID 28614791 ↗ Jun 2017 |